Abstract
Multi-drug resistance (MDR) presents a serious problem in cancer chemotherapy. In this study, Vitamin E (VE)-Albumin core-shell nanoparticles were developed for paclitaxel (PTX) delivery to improve the chemotherapy efficacy in an MDR breast cancer model. The PTX-loaded VE-Albumin core-shell nanoparticles (PTX-VE NPs) had small particle sizes (about 100 nm), high drug entrapment efficiency (95.7%) and loading capacity (12.5%), and showed sustained release profiles, in vitro. Docking studies indicated that the hydrophobic interaction and hydrogen bonds play a significant role in the formation of the PTX-VE NPs. The results of confocal laser scanning microscopy analysis demonstrated that the cell uptake of PTX was significantly increased by the PTX-VE NPs, compared with the NPs without VE (PTX NPs). The PTX-VE NPs also exhibited stronger cytotoxicity, compared with PTX NPs with an increased accumulation of PTX in the MCF-7/ADR cells. Importantly, the PTX-VE NPs showed a higher anti-cancer efficacy in MCF-7/ADR tumor xenograft model than the PTX NPs and the PTX solutions. Overall, the VE-Albumin core-shell nanoparticles could be a promising nanocarrier for PTX delivery to improve the chemotherapeutic efficacy of MDR cancer.
Highlights
Multi-drug resistance (MDR) is a large obstacle to the success of cancer chemotherapy and is crucial to cancer metastasis and recovery [1]
The PTX-Vitamin E (VE) NPs were fabricated by the desolvation-ultrasonication method
The PTX-VE NPs was formed by the interaction among the PTX, VE, and BSA
Summary
Multi-drug resistance (MDR) is a large obstacle to the success of cancer chemotherapy and is crucial to cancer metastasis and recovery [1]. The well-known P-glucoprotein (P-gp), an ATP-binding cassette transporter, which is over expressed on the surface membrane of cancer cells, is one of the major reasons for the cancer MDR [2]. Many P-gp substrates, such as paclitaxel, were expelled out of the cancer cells, resulting in the reduction of intracellular drug accumulation, thereby leading to the treatment failure [3]. It is urgent to explore a more effective strategy for overcoming the cancer MDR. Paclitaxel (PTX), a water-insoluble compound, is used widely as a fist-line drug in clinical treatment against variety of cancers [4]. PTX is commonly formulated as Taxol® , which uses
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
